This episode of Odd Lots explores the rapid rise of China’s biotech sector, where Chinese firms now account for 31% of molecules licensed to big pharma, up from 0% in 2019. Stifel’s Tim Opler discusses how returning scientists, lower clinical trial costs, and broader shifts in the pharmaceutical industry have fueled this growth, while also touching on AI’s potential impact on drug discovery. Read the article here
